MedTrace Logo

Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

NCT07606352 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-05-26

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients. About 15 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of STL303 or placebo capsules orally according to protocol.

Conditions

Interventions

DRUG

Placebo capsule

Placebo arm participants will receive placebo capsules

DRUG

STL303

STL303 arm participants will receive a specific dose of STL303

DRUG

STL303

STL303 arm participants will receive a specific dose of STL303

Sponsors & Collaborators

  • Sitala Bio LTD

    lead INDUSTRY

Principal Investigators

  • Eugenia Pedagogos · Western Health (Sunshine Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-07-31
Completion
2027-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606352 on ClinicalTrials.gov